Compare Lockheed Martin Corporation (LMT) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lockheed Martin Corporation vs Natera Inc. Common Stock — how do they compare? Lockheed Martin Corporation trades at $525.61 (market cap $116.32B), while Natera Inc. Common Stock trades at $394.16 (market cap $57.03B). The key difference: Lockheed Martin Corporation is far larger — about 2× Natera Inc. Common Stock's market cap, and Lockheed Martin Corporation pays a 2.86% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lockheed Martin Corporation for 86 Days and Natera Inc. Common Stock for 0 Days on average.
| LMT | NTRA | |
|---|---|---|
Market Cap | $116.32B | $57.03B |
Volume | 860,316 | 1,131,157 |
Sector | Industrials | Health |
52-Week High | $676.70 | $425.64 |
52-Week Low | $439.19 | $179.42 |
Typical Hold Time | 86 Days | 0 Days |
Enterprise Value | $133.07B | $56.18B |
Dividend Yield | 2.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lockheed Martin (LMT) trades at $522.23, up 2.02% today, with a bearish technical signal and neutral oscillators. The company reported revenue of $75.05 billion in 2025, with net income of $5.02 billion, though recent quarters show mixed earnings results. Analysts maintain a strong buy consensus with a $625.64 price target. Recent news highlights ongoing dividend increases, AI integration efforts, and new defense contracts, supporting long-term growth prospects amid stable cash flows.
The outlook for LMT is positive, driven by robust defense spending and strategic innovations, but risks include reliance on government contracts and fixed-price contract volatility. The stock offers value with a P/E of 18.58 and a dividend yield supported by 23 years of increases, though technical indicators suggest near-term caution.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
